Fixed-Duration Acalabrutinib/Venetoclax in Fit Patients With CLL: AMPLIFY Trial - report from ASH2024

from Medical Digest & Congress Report · host Medical Congress News

Jennifer R. Brown, MD, PhD explains the interim analysis of the multicenter, open-label, randomized, phase 3 AMPLIFY trial presented at the 2024 ASH Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:fixed-duration-acalabrutinibvenetoclax-fit-patients-cll-amplify-trial

Episode metadata supplied by the publisher feed · Published Dec 20, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

Fixed-Duration Acalabrutinib/Venetoclax in Fit Patients With CLL: AMPLIFY Trial - report from ASH2024

0:00 7:22

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 7 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on December 20, 2024.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!